SEHK:2171Biotechs
How Early Allogeneic CAR T Results At CARsgen (SEHK:2171) Have Changed Its Investment Story
CARsgen Therapeutics Holdings recently presented early clinical data at the 2026 European Hematology Association Congress showing its allogeneic CAR T-cell candidates CT0596 and CT1190B produced high response rates with manageable safety in heavily pretreated blood cancer patients.
An interesting aspect for investors is that both products are off-the-shelf allogeneic CAR T therapies, with responses seen even in patients previously treated with CAR T or bispecific antibodies.
We will now...